Cyclophosphamide (NCT03412877)

Name: Cyclophosphamide trial for Endocrine Tumors (NCT03412877)
Uploaded: 2026-10-31T16:01:27.469Z
Duration: 1 min 23 s
Description: Cyclophosphamide trial for Endocrine Tumors (NCT03412877). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03412877.

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer: a one-minute explainerNCT034128771 min

Cyclophosphamide trial for Endocrine Tumors (NCT03412877). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 18–72 with eligible metastatic cancers after standard-treatment failure. Myeloma with solid masses has additional requirements, including four previous treatment lines and an autologous transplant.

The idea: collect patients’ T-cells and engineer receptors that recognize targets in their cancer. After lymphodepleting chemotherapy, patients receive these cells and aldesleukin. One arm adds pembrolizumab; patients with severe checkpoint-related organ toxicity may enter the other arm. Researchers assess response. Tumor sampling and hospitalization are required.

This phase 2 study plans 285 patients. Steven Rosenberg leads at NIH’s recruiting Bethesda site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.